CD19 and BCMA-targeted allogeneic CAR-T cells: Clinical Trials

1 trial of CD19 and BCMA-targeted allogeneic CAR-T cells, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1

Follow CD19 and BCMA-targeted allogeneic CAR-T cells: new trials by email Literature Review of CD19 and BCMA-targeted allogeneic CAR-T cells trials Research Report on CD19 and BCMA-targeted allogeneic CAR-T cells

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
CD19 and BCMA-targeted allogeneic CAR-T cells - Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
Phase 1RecruitingThe First Affiliated Hospital of Soochow University92025-07-072026-06-12

Conditions studied

Purpura, Thrombocytopenic, Idiopathic (1)  ·  Recurrence (1)

Sponsors

The First Affiliated Hospital of Soochow University (1)

Countries

China (1)